Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH

Pasadena. CA | Posted on March 3rd, 2020

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “Genetic studies have recently pointed to HSD17B13 as a compelling target for multiple forms of liver disease. No other therapeutics against this target have reached clinical studies, so ARO-HSD is the first investigational medicine using any modality to initiate a clinical program to study whether HSD17B13 inhibition in the liver leads to a clinical benefit for patients. Further, based on our preclinical work and key findings from various studies with our other product candidates, we believe that an RNAi-based intervention that utilizes our proprietary TRiMTM platform has the potential to be highly active at silencing the expression of HSD17B13.”

AROHSD1001 (NCT04202354) is a Phase 1/2 single and multiple dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ARO-HSD in up to 74 normal healthy volunteers and patients with NASH or suspected NASH. Additional exploratory objectives include the assessment of various measures of drug activity using liver biopsy.

HSD17B13 is a member of the hydroxysteroid dehydrogenase family involved in the metabolism of hormones, fatty acids, and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against alcoholic hepatitis, cirrhosis, and NASH, with approximately 30-50% risk reduction compared to non-carriers.1

1The New England Journal of Medicine. 2018, 1096-1106

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

An EPiQS Pursuit: Physicist Andrea Young is chosen to receive an Experimental Investigator award from the Moore Foundation May 28th, 2020

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Surrey reveals its implantable biosensor that operates without batteries May 22nd, 2020

Researchers demonstrate transport of mechanical energy, even through damaged pathways: Topological pump can provide stability for communication technologies May 22nd, 2020

Govt.-Legislation/Regulation/Funding/Policy

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Scientists use light to accelerate supercurrents, access forbidden light, quantum world May 21st, 2020

Electrons break rotational symmetry in exotic low-temp superconductor: Scientists previously observed this peculiar behavior in other materials whose ability to conduct electricity without energy loss cannot be explained by standard theoretical frameworks May 19th, 2020

Scientists break the link between a quantum material's spin and orbital states: The advance opens a path toward a new generation of logic and memory devices based on orbitronics that could be 10,000 times faster than today's May 15th, 2020

Nanomedicine

2D sandwich sees molecules with clarity: Rice University engineers adapt 2D ‘sandwich’ for surface-enhanced Raman spectroscopy May 15th, 2020

Twisting 2D materials uncovers their superpowers: Researchers have developed a completely new method for twisting atomically thin materials, paving the way for applications of 'twistronics' based on tunable 2D materials May 12th, 2020

Chemistry breakthrough could speed up drug development: Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development May 8th, 2020

Engineers and scientists develop mobile technology for eye examinations: Novel photonic integrated technology will bring optical coherence tomography from stationary clinical use to mobile use May 7th, 2020

Announcements

An EPiQS Pursuit: Physicist Andrea Young is chosen to receive an Experimental Investigator award from the Moore Foundation May 28th, 2020

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Visualization of functional components to characterize optimal composite electrodes May 22nd, 2020

Researchers demonstrate transport of mechanical energy, even through damaged pathways: Topological pump can provide stability for communication technologies May 22nd, 2020

Nanobiotechnology

2D sandwich sees molecules with clarity: Rice University engineers adapt 2D ‘sandwich’ for surface-enhanced Raman spectroscopy May 15th, 2020

Chemistry breakthrough could speed up drug development: Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development May 8th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences May 1st, 2020

Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given May 1st, 2020

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project